We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.475 | 1,048,058 | 07:34:47 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.45 | 0.50 | 0.475 | 0.475 | 0.475 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 2k | -1.27M | -0.0032 | -1.47 | 1.88M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:27:25 | O | 208,671 | 0.49 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/2/2025 | 12:34 | UK RNS | N4 Pharma PLC Holding(s) in Company |
| 07/2/2025 | 07:00 | UK RNS | N4 Pharma PLC Investor Webinar |
| 27/1/2025 | 07:00 | UK RNS | N4 Pharma PLC Investor Webinar |
| 16/1/2025 | 07:00 | UK RNS | N4 Pharma PLC N4 Pharma Non-Executive Director Q&A |
| 08/1/2025 | 07:00 | UK RNS | N4 Pharma PLC Directorate Changes |
| 12/12/2024 | 07:00 | UK RNS | N4 Pharma PLC N4 101 In Vitro Results |
| 04/12/2024 | 07:00 | UK RNS | N4 Pharma PLC New Patent Filing |
| 28/11/2024 | 07:00 | UK RNS | N4 Pharma PLC Grant of Options |
| 01/11/2024 | 07:00 | UK RNS | N4 Pharma PLC N4 Pharma CEO Q&A Now LIVE |
| 24/10/2024 | 06:00 | UK RNS | N4 Pharma PLC New Corporate Presentation |
N4 Pharma (N4P) Share Charts1 Year N4 Pharma Chart |
|
1 Month N4 Pharma Chart |
Intraday N4 Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/3/2025 | 12:52 | N4 Pharma | 4,295 |
| 06/3/2025 | 12:20 | ShareSoc & InvestorHub Discovery Company Webinar | 11 |
| 20/5/2021 | 07:25 | N4 Pharma - Making good drugs better. | 4,391 |
| 14/9/2020 | 06:40 | N4P Covid-19 Wealth Warning | 108 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/3/2025 08:20 by N4 Pharma Daily Update N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.48p.N4 Pharma currently has 394,780,000 shares in issue. The market capitalisation of N4 Pharma is £1,855,466. N4 Pharma has a price to earnings ratio (PE ratio) of -1.47. This morning N4P shares opened at 0.48p |
Posted at 12/3/2025 12:52 by pwal Whether it's this week or next, N4P is expecting approval. |
Posted at 12/3/2025 08:27 by featherby81 It seems the ODD application is trickier than first thought, not sure Nigel made it easier by stating “As well as glaucoma, the MRTF-B gene is also responsible for fibrosis of the liver and lung, two large areas into which Nanogenics could develop its portfolio” in RNS on 28-9-23. Is it or is it not what the FDA are looking to clamp down on?I can’t access your devices so can’t prove you have a screenshot, although you do have access to that screenshot that you could share if you really wanted to, I suspect you’ll avoid doing it. I’m a LT shareholder that sees huge upside in Nuvec, it’s a crazy valuation right now with the two products and I fully back the board’s approach with going into product development, so please refrain from saying I’m a bb disrupter or a stock basher. |
Posted at 06/3/2025 12:20 by sharesoc If you missed this Webinar the recording is now available!Hear from SEEEN plc (SEEN) and N4 Pharma PLC (N4P) as they discuss their latest developments and future outlook. If you couldn’t attend live, this is your chance to catch up. Watch here: |
Posted at 18/2/2025 15:42 by earwacks Or a lot of money to risk. The Indian guy who bought in a year ago had a percent top up a couple of weeks back. Viagra is a drug that was formulated to combat blood pressure but ended up the most successful treatment for erectile dysfunction. Phzer got lucky with that one. But of course they had a very successful business to back it. Nigel has created a product that he is desperately seeking a market for with no back up. The trouble is he assumes that eventually someone will find a use for it. The worry is that nobody thus far is that interested, or at least they are not rushing to bite his hand off. That in itself is disappointing. The other more serious problem is there is literally no business and never has been. So the idea that is undervalued is absurd. It is worth the cash they still have until they can sell something. No point in him and now Dr Smith trying to talk the price up, Nigel has failed too many times previously. Not saying there is no potential, because there clearly is, but one has to question his business nose and the fact that they don’t seem to be queuing up for Nuvec or Nanogenics. He was the only bidder for that company. Maybe it will turn out to have been a shrewd purchase. Again at the present time it has zero value until proved otherwise |
Posted at 12/2/2025 10:43 by pwal This share has to be tipped somewhere. |
Posted at 10/2/2025 11:42 by sharesoc Discovery Company Webinar – 25 February, 5pmShareSoc, in collaboration with InvestorHub, presents the next Discovery Company Webinar, featuring: * N4 Pharma PLC (N4P) * SEEEN plc (SEEN) Hear from the CEOs of both companies as they provide insights into their current progress and future plans. Register here: |
Posted at 23/11/2024 09:37 by pwal Tweet:The @humancellatlas is transforming our understanding of health and disease. With newly uncovered cell types, including those linked to inflammation in #IBD, advanced therapies targeting specific cells such as Nuvec®, will be more in demand: bbc.co.uk/news/artic |
Posted at 11/11/2024 13:49 by pwal Who thinks N4P can hit 1p before the end of the year? |
Posted at 25/10/2024 12:28 by fido People should take a look at the PDF.In it the company clearly states that the upside from here is 20-50 times which would value N4P at more than 100 million. |
Posted at 24/10/2024 08:35 by pwal Well I guess now is the time to stock up on N4P. But it will be a slow burner.The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
